Abaloparatide
Synthetic PTHrP 1-34 analog approved 2017 (FDA) for severe postmenopausal osteoporosis. | Compound
Aliases (3)
▸ Overview TL;DR
Synthetic PTHrP 1-34 analog approved 2017 (FDA) for severe postmenopausal osteoporosis. Same general anabolic-bone class as teriparatide but engineered for greater receptor selectivity that produces faster trabecular bone gain with less hypercalcemia. NOT-RELEVANT for Dylan (20yo, peak BMD, no fracture history); documented as the cousin of teriparatide for completeness.
▸ Mechanism of action
Abaloparatide is a synthetic 34-amino-acid peptide modeled on parathyroid hormone-related protein (PTHrP), the same family as parathyroid hormone but with distinct receptor-conformation preference.
Receptor pharmacology — the key engineering insight:
- PTH1R (the parathyroid hormone receptor) exists in two main conformations:
- R0 — high-affinity, prolonged signaling (favors sustained activation → catabolic to bone, hypercalcemic)
- RG — transient signaling, G-protein coupled (favors brief activation → preferentially anabolic to bone)
- Teriparatide (PTH 1-34) binds both R0 and RG roughly equally
- Abaloparatide (PTHrP 1-34 analog) binds RG preferentially, with much weaker R0 affinity
Practical consequence: abaloparatide produces a sharper, more transient PTH1R activation per dose, which translates clinically to:
- Faster trabecular bone gain (especially femoral neck, lumbar spine)
- Less hypercalcemia (clinically meaningful — easier to manage in real-world prescribing)
- Similar overall fracture-prevention efficacy
The fundamental "intermittent PTH receptor activation favors bone formation over resorption" paradox — same as teriparatide:
- Brief SC dose produces short PTH1R signaling spike
- Osteoblast lineage cells receive anabolic Wnt/Runx2/IGF-1 signaling
- Modeling-based bone formation outpaces resorption
- Net BMD gain over 18-24 month "anabolic window"
- Continued use beyond ~2 years loses effect — receptor desensitization and resorption catches up
▸ Pharmacokinetics No data
▸Research indications2 use cases
R0
Most effectivehigh-affinity, prolonged signaling (favors sustained activation → catabolic to bone, hypercalcemic)
RG
Effectivetransient signaling, G-protein coupled (favors brief activation → preferentially anabolic to bone)
▸ What to expect Generic
- 1Week 1Tolerability and dose-response.
- 2Week 2-4Early effect window.
- 3Week 4-8Peak benefit assessment.
- 4Week 8+Cycle decision point.
▸ Side effects + safety
- Common (>10%): Injection-site reaction (erythema, mild pain), nausea, headache, dizziness
- Less common (1-10%): Orthostatic hypotension within 4 hours of dose, palpitations, hypercalcemia (3-4% — meaningfully lower than teriparatide's ~6%), abdominal pain, vertigo
- Rare-serious (<1%): Osteosarcoma (rodent signal at supratherapeutic chronic doses; black-box warning carried over from teriparatide; no confirmed human cases linked to abaloparatide)
- Specific watch periods: First few doses — orthostatic hypotension is most common in first hour. Patients are typically advised to sit down for several minutes after injection. Calcium monitoring at 1-3 months.
▸Interactions5 compounds
- Antiresorptives (alendronate, denosumab) post-course:SynergisticLocks in gains
- Vitamin D3 + calcium:SynergisticRequired co-administration — anabolic peptide demands calcium and D substrate
- Vitamin K2 (MK-7):SynergisticTheoretical support for calcium-direction-to-bone vs vascular calcification
- Teriparatide concurrently or sequentially without break:AvoidSame receptor — additive osteosarcoma signal concern
- Other PTH receptor agonistsAvoid